175 related articles for article (PubMed ID: 35131363)
1. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study.
Thase ME; Jacobsen PL; Hanson E; Xu R; Tolkoff M; Murthy NV
J Affect Disord; 2022 Apr; 303():123-130. PubMed ID: 35131363
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
3. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
Jacobsen P; Zhong W; Xu R; Nomikos G
J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
6. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
Wang J; Liu XF; Feng C; Bao Q; Fu HR
Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
[No Abstract] [Full Text] [Related]
12. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
Christensen MC; Florea I; Loft H; McIntyre RS
J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
[TBL] [Abstract][Full Text] [Related]
15. Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials.
Gao S; Xie X; Fan L; Zhang D
Exp Ther Med; 2023 Nov; 26(5):515. PubMed ID: 37840562
[TBL] [Abstract][Full Text] [Related]
16. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
[TBL] [Abstract][Full Text] [Related]
18. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
McIntyre RS; Florea I; Pedersen MM; Christensen MC
J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
[No Abstract] [Full Text] [Related]
19. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
Zheng J; Wang Z; Li E
Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder.
Christensen MC; McIntyre RS; Adair M; Florea I; Loft H; Fagiolini A
CNS Spectr; 2023 Dec; 28(6):693-701. PubMed ID: 37070529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
